Last reviewed · How we verify

NCT03693040

Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

Status unknown NA Last updated 23 December 2022
What this trial tests

NA trial testing Digital Health Feedback System in HIV Prevention in 100 participants. Status unknown.

Timeline
1 December 2016
Primary endpoint
31 December 2021
31 December 2022

Quick facts

Lead sponsorUniversity of California, San Diego
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment100
Start date1 December 2016
Primary completion31 December 2021
Estimated completion31 December 2022
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Diego

Who can join

18 and older, any sex, with HIV Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new Proteus Digital Health (PDH) technologies approved by the FDA, to collect information about patients taking their Pre-Exposure Prophylaxis (PrEP) medication for HIV prevention. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which gives healthcare providers information about when patients have taken their PrEP medication. The purpose of the study is to demonstrate that the DHFS is easy to use and acceptable to people taking PrEP; that patients will persist with its use; and that the system provides valid, accurate measures of adherence.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Digital Pills with Ingestible Sensors: Patent Landscape Analysis.
    Litvinova O, Klager E, Tzvetkov NT, Kimberger O, et al · · 2022 · cited 13× · PMID 36015173 · DOI 10.3390/ph15081025
  2. Ingestible Electronic Sensors for Monitoring Real-time Adherence to HIV Pre-exposure Prophylaxis and Antiretroviral Therapy.
    Goodman GR, Vaz C, Albrechta H, Boyer EW, et al · · 2022 · cited 7× · PMID 36048309 · DOI 10.1007/s11904-022-00625-x
  3. Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection.
    Browne SH, Vaida F, Umlauf A, Tucker AJ, et al · · 2023 · cited 6× · PMID 36484300 · DOI 10.1093/cid/ciac280
  4. Bibliometric analysis and evidence of clinical efficacy and safety of digital pills.
    Litvinova O, Klager E, Yeung AWK, Tzvetkov NT, et al · · 2023 · cited 3× · PMID 36755951 · DOI 10.3389/fphar.2023.1023250
  5. User Experience of Persons Using Ingestible Sensor-Enabled Pre-Exposure Prophylaxis to Prevent HIV Infection: Cross-Sectional Survey Study.
    Browne S, Umlauf A, Moore DJ, Benson CA, et al · · 2024 · PMID 38722201 · DOI 10.2196/53596

Verify or expand the search:

Other trials of Digital Health Feedback System

Trials testing the same drug.

Other recruiting trials for HIV Prevention

Currently open trials in the same condition.

Other University of California, San Diego trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03693040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing